Hemostasis tests are used mainly for the diagnosis and treatment of hemorrhagic diseases (e.g., hemophilia) and thrombotic diseases (e.g., myocardial infarction and cerebral infarction). In recent years, with an increase in thrombotic diseases attributable to patient lifestyle and/or age, and with the development of new blood products designed to improve the quality of life (QOL) of patients with hemorrhagic diseases, the need for hemostasis tests for early diagnosis and proper treatment of these diseases has become more diverse. On the other hand, hemostasis tests generally use multiple devices with different measurement principles, including immunoassay instruments and platelet aggregometers. This has created issues in the clinical setting, such as complicated screening workflows and delays in obtaining test results needed to understand patients’ conditions and treat them.
Sysmex provides the Automated Blood Coagulation Analyzers, which enable the flexible measurement of coagulation molecular markers using the CLEIA method*
, as well as blood coagulation and platelet aggregation parameters, in response to a wide range of testing orders in the thrombosis and hemostasis areas. These analyzers provide efficient screening workflows that meet various needs in the clinical setting.
Moreover, the combined use of Caresphere, our network solution, allows customers to easily check and analyze, from remote locations, the number of processed specimens, remaining quantities of consumables such as reagents, operation of equipment including the results of quality control, and the operational status of laboratories overall. This helps raise the efficiency of routine operations in laboratories.
- Chemiluminescence enzyme immunoassay